JP5650404B2 - Ｎ−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法 - Google Patents

Ｎ−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法 Download PDF

Info

Publication number
JP5650404B2
JP5650404B2 JP2009544239A JP2009544239A JP5650404B2 JP 5650404 B2 JP5650404 B2 JP 5650404B2 JP 2009544239 A JP2009544239 A JP 2009544239A JP 2009544239 A JP2009544239 A JP 2009544239A JP 5650404 B2 JP5650404 B2 JP 5650404B2
Authority
JP
Japan
Prior art keywords
piperidin
yloxy
benzamide
benzylpiperidin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009544239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514788A (ja
JP2010514788A5 (enExample
Inventor
ラジンダー シン，
ラジンダー シン，
チアシン ユー，
チアシン ユー，
ホイ ホン，
ホイ ホン，
サンバイアー ソタ，
サンバイアー ソタ，
シャン スー，
シャン スー，
Original Assignee
ライジェル ファーマシューティカルズ， インコーポレイテッド
ライジェル ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライジェル ファーマシューティカルズ， インコーポレイテッド, ライジェル ファーマシューティカルズ， インコーポレイテッド filed Critical ライジェル ファーマシューティカルズ， インコーポレイテッド
Publication of JP2010514788A publication Critical patent/JP2010514788A/ja
Publication of JP2010514788A5 publication Critical patent/JP2010514788A5/ja
Application granted granted Critical
Publication of JP5650404B2 publication Critical patent/JP5650404B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2009544239A 2006-12-28 2007-12-21 Ｎ−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法 Expired - Fee Related JP5650404B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88231206P 2006-12-28 2006-12-28
US60/882,312 2006-12-28
US98871907P 2007-11-16 2007-11-16
US60/988,719 2007-11-16
PCT/US2007/088742 WO2008083124A1 (en) 2006-12-28 2007-12-21 N-substituted-heterocycloalkyloxybenzamide compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2010514788A JP2010514788A (ja) 2010-05-06
JP2010514788A5 JP2010514788A5 (enExample) 2012-01-26
JP5650404B2 true JP5650404B2 (ja) 2015-01-07

Family

ID=39204919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009544239A Expired - Fee Related JP5650404B2 (ja) 2006-12-28 2007-12-21 Ｎ−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法

Country Status (6)

Country Link
US (3) US8012955B2 (enExample)
EP (1) EP2079694B1 (enExample)
JP (1) JP5650404B2 (enExample)
CA (1) CA2674237C (enExample)
ES (1) ES2627221T3 (enExample)
WO (1) WO2008083124A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008322426C1 (en) 2007-11-16 2014-10-23 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2231666B1 (en) * 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
CN104016980B (zh) * 2008-04-23 2016-12-07 里格尔药品股份有限公司 用于治疗代谢障碍的甲酰胺化合物
ES2581678T3 (es) 2009-01-28 2016-09-06 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida y métodos para usar los mismos
GB0912975D0 (en) * 2009-07-24 2009-09-02 Syngenta Ltd Formulations
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011123681A1 (en) 2010-03-31 2011-10-06 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
WO2011142359A1 (ja) * 2010-05-10 2011-11-17 日産化学工業株式会社 スピロ化合物及びアディポネクチン受容体活性化薬
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
MX338707B (es) 2010-07-29 2016-04-28 Rigel Pharmaceuticals Inc Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos.
EP2630144B1 (en) 2010-10-19 2016-09-07 Boehringer Ingelheim International GmbH Rho kinase inhibitors
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9409884B2 (en) 2012-02-01 2016-08-09 Rigel Pharmaceuticals, Inc. 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
EP3053911B1 (en) 2013-09-30 2020-01-22 The University of Tokyo Adiponectin receptor-activating compound
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
US9832291B2 (en) 2015-01-12 2017-11-28 Cisco Technology, Inc. Auto-configurable transport stack
CN104803914B (zh) * 2015-03-05 2017-11-14 成都理工大学 作为Rho激酶抑制剂的六氢氮杂卓氧基苯甲酰胺类化合物
CN110372638B (zh) * 2018-04-13 2023-09-22 中国药科大学 哌嗪类ampk激动剂及其医药用途
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8406906D0 (en) 1984-03-16 1984-04-18 Akzo Nv Benzo-thiazole and benzothiophene derivatives
JPH0784462B2 (ja) 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) * 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US5438064A (en) * 1991-12-23 1995-08-01 American Home Products Corporation Derivatives of 4-anilinoquinoline-3-carboxamide as analgesic agents
US5332732A (en) * 1992-09-11 1994-07-26 Mcneilab, Inc. Thiophene and pyridine antipsychotic agents
WO1995002405A1 (en) * 1993-07-16 1995-01-26 Merck & Co., Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
WO1996006837A1 (en) * 1994-08-30 1996-03-07 Sankyo Company, Limited Isoxazoles
FR2738569B1 (fr) * 1995-09-12 1997-11-28 Pf Medicament Nouveaux derives naphtamide de 3 beta-amino azabicyclo octane ou nonane, leur procede de preparation, leur utilisation a titre de medicament antipsychotique
PT1077931E (pt) 1998-05-15 2005-03-31 Astrazeneca Ab Derivados de bezamida para o tratamento de doencas mediadas por citocinas
MXPA01002173A (es) 1998-08-28 2003-07-14 Scios Inc Inhibidores de p38-alfa cinasa.
CA2368829A1 (en) * 1999-04-09 2000-10-19 Astrazeneca Ab Adamantane derivatives
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
US7361678B2 (en) * 2002-03-05 2008-04-22 Transtech Pharma, Inc. Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
WO2002051809A1 (en) * 2000-12-22 2002-07-04 Schering Corporation Piperidine mch antagonists and their use in the treatment of obesity
US20030216582A1 (en) * 2001-02-08 2003-11-20 Nicholas Nikolaides 2-carboxamide-benzimidazoles useful in the treatment and prevention of ischemic reperfusion injury
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
CA2455773A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-aryl 7-aza¬2.2.1|bicycloheptanes for the treatment of disease
DE60218493D1 (de) 2001-09-12 2007-04-12 Pharmacia & Upjohn Co Llc Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
CA2460594A1 (en) 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
JP2005523288A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
JP2005525357A (ja) * 2002-02-20 2005-08-25 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー α７ニコチン性アセチルコリン受容体活性を伴うアザ二環式化合物
EP1500643A4 (en) * 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co BENZAMIDE DERIVATIVES
CA2484233A1 (en) 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
KR100962972B1 (ko) * 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
AU2003263393A1 (en) * 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
PL377087A1 (pl) 2002-09-06 2006-01-23 Janssen Pharmaceutica, N.V. Związki heterocykliczne
CA2509711A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US7208491B2 (en) * 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
WO2004076420A1 (ja) * 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
ES2328819T3 (es) * 2003-04-07 2009-11-18 Pharmacyclics, Inc. Hidroxamatos como agentes terapeuticos.
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
GB0314054D0 (en) 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
EP1660439A2 (en) 2003-08-08 2006-05-31 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
BRPI0410727A (pt) * 2003-08-20 2006-06-20 Axys Pharm Inc composto, composição farmacêutica, e, uso de um composto
JP4895811B2 (ja) 2003-09-11 2012-03-14 ケミア，インコーポレイテッド サイトカイン阻害剤
AU2004303790A1 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
JP4760139B2 (ja) * 2004-05-28 2011-08-31 田辺三菱製薬株式会社 ピロリジン誘導体およびその製法
CA2566526C (en) * 2004-06-02 2012-10-23 F. Hoffmann-La Roche Ag Naphthaline derivatives useful as histamine-3-receptor ligands
WO2005123716A1 (en) * 2004-06-21 2005-12-29 F. Hoffmann-La Roche Ag Indole derivatives as histamine receptor antagonists
JP2007277096A (ja) 2004-07-15 2007-10-25 Astellas Pharma Inc フェネチルニコチンアミド誘導体含有医薬
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
EP1805166B1 (en) * 2004-10-19 2011-07-27 F. Hoffmann-La Roche AG Quinoline derivatives
CA2587141A1 (en) 2004-11-24 2006-06-01 Pfizer Inc. Octahydropyrrolo[3,4-c]pyrrole derivatives
NZ555444A (en) * 2004-11-29 2011-01-28 Vertex Pharma Modulators of muscarinic receptors
AR052342A1 (es) 2004-12-21 2007-03-14 Janssen Pharmaceutica Nv Derivados sustituidos de triazolona,tetrazolona e imidazolona con actividad selectiva antagonista de alfa2c-adenoreceptores
EA200701114A1 (ru) 2004-12-23 2007-12-28 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Азоловые производные с антимускариновой активностью
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
KR20080027908A (ko) 2005-06-30 2008-03-28 프로시디온 리미티드 Ｇｐｃｒ 효능제
WO2007057329A1 (en) 2005-11-18 2007-05-24 F. Hoffmann-La Roche Ag Azaindole-2-carboxamide derivatives
RU2412182C2 (ru) * 2005-11-30 2011-02-20 Ф.Хоффманн-Ля Рош Аг Производные 1,1-диоксотиоморфолинилиндолилметанона для применения в качестве модуляторов гистамина 3 (н3)
ATE466007T1 (de) * 2005-11-30 2010-05-15 Hoffmann La Roche 5-substituierte indol-2-carbonsäureamidderivate
CN101316840B (zh) * 2005-11-30 2012-08-08 霍夫曼-拉罗奇有限公司 1,5-取代的吲哚-2-基酰胺衍生物
CA2632719A1 (en) 2005-12-09 2007-06-14 Solvay Pharmaceuticals Gmbh Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
AU2006331850A1 (en) 2005-12-21 2007-07-05 Schering Corporation Substituted aniline derivatives useful as histamine H3 antagonists
WO2007073935A1 (en) 2005-12-29 2007-07-05 Lek Pharmaceuticals D.D. Heterocyclic compounds
EP1991233A4 (en) * 2006-02-17 2009-07-01 Avalon Pharmaceuticals Hydroxypiperidine derivatives and their use
EP2032566A4 (en) 2006-06-12 2009-07-08 Merck Frosst Canada Ltd AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
CA2654098A1 (en) 2006-06-13 2007-12-21 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US20080085915A1 (en) 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
TW200821303A (en) 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
WO2008133975A1 (en) 2007-04-26 2008-11-06 Avalon Pharmaceuticals Multi-ring compounds and uses thereof
AU2008322426C1 (en) 2007-11-16 2014-10-23 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2231666B1 (en) 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
CN104016980B (zh) 2008-04-23 2016-12-07 里格尔药品股份有限公司 用于治疗代谢障碍的甲酰胺化合物

Also Published As

Publication number Publication date
ES2627221T3 (es) 2017-07-27
JP2010514788A (ja) 2010-05-06
US20110306767A1 (en) 2011-12-15
US9181220B2 (en) 2015-11-10
CA2674237A1 (en) 2008-07-10
US8012955B2 (en) 2011-09-06
US20090186894A1 (en) 2009-07-23
CA2674237C (en) 2015-11-24
US8697727B2 (en) 2014-04-15
WO2008083124A1 (en) 2008-07-10
EP2079694A1 (en) 2009-07-22
US20140179738A1 (en) 2014-06-26
EP2079694B1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
JP5650404B2 (ja) Ｎ−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法
US10941134B2 (en) AMPK-activating heterocyclic compounds and methods for using the same
JP5544296B2 (ja) 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
CA2750835C (en) Carboxamide compounds and methods for using the same
WO2013116491A1 (en) Carboxamide, sulfonamide and amine compounds and methods for using them
HK1164860B (en) Carboxamide compounds and methods for using the same
HK1148525B (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141113

R150 Certificate of patent or registration of utility model

Ref document number: 5650404

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees